We are studying how hematopoietic cell fate is specified, maintained, and eventually modified or reversed. Inspired from the fields of stem cell biology, immunology, and cancer we use an interdisciplinary approach to mechanistically understand hematopoietic and immune cell identities and translate our findings into novel gene and cell therapies.
Cell Fate Reprogramming in the Era of Cancer Immunotherapy
Olga Zimmermannova, Inês Caiado, Alexandra G. Ferreira and Carlos-Filipe Pereira
July 21, 2021 / Volume 12, Article 714822
Frontiers in Immunology
Reprogramming, The Journal
June 17, 2021 / Volume 23, Number 3
We are a diverse group – molecular biologists, MDs, PharmDs, tumor immunologists, stem cell biologists and computational scientists – at all career stages. We architect strategies to dissect and manipulate immune cell identity.
Looking for an opportunity? Join our international team!
Spin-off From Pereira Lab Raises 6M Euros to Advance In vivo DC Reprogramming
Asgard Therapeutics AB, a private biotech company spin off from the Pereira Lab, announces the completion of a EUR 6 million seed financing round. The financing was co-led by Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden.
Fábio Rosa Defended His PhD Thesis
On June 10th 2021, Fábio Rosa defended his thesis “Generating Dendritic Cells by Direct Cell Reprogramming. Merging cellular reprogramming with immunology towards the development of novel cancer immunotherapies.” with Prof. Thomas Graf from the Center for Genomic Regulation (Spain) as opponent.
Filipe Pereira Is The New Editor-in-Chief of Cellular Reprogramming
Following on the legacy of Professor Sir Ian Wilmut, Filipe Pereira becomes the new Editor-in-Chief of the Cellular Reprogramming Journal.